Literature DB >> 28443617

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Robin L Carhart-Harris1, Guy M Goodwin2.   

Abstract

Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady revival of human psychedelic research: last year saw reports on the first modern brain imaging study with LSD and three separate clinical trials of psilocybin for depressive symptoms. In this circumspective piece, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28443617      PMCID: PMC5603818          DOI: 10.1038/npp.2017.84

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  70 in total

1.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

Authors:  Katherine A MacLean; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2011-09-28       Impact factor: 4.153

2.  Culture as a mediator of gene-environment interaction: Cultural consonance, childhood adversity, a 2A serotonin receptor polymorphism, and depression in urban Brazil.

Authors:  William W Dressler; Mauro C Balieiro; Luiza Ferreira de Araújo; Wilson A Silva; José Ernesto Dos Santos
Journal:  Soc Sci Med       Date:  2016-05-21       Impact factor: 4.634

Review 3.  Psychedelics in the treatment of unipolar mood disorders: a systematic review.

Authors:  James Jh Rucker; Luke A Jelen; Sarah Flynn; Kyle D Frowde; Allan H Young
Journal:  J Psychopharmacol       Date:  2016-11-17       Impact factor: 4.153

4.  Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects.

Authors:  R J Strassman; C R Qualls
Journal:  Arch Gen Psychiatry       Date:  1994-02

Review 5.  Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities.

Authors:  Bradley N Gaynes
Journal:  J Clin Psychiatry       Date:  2009       Impact factor: 4.384

6.  Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations.

Authors:  Holger J Schünemann; Atle Fretheim; Andrew D Oxman
Journal:  Health Res Policy Syst       Date:  2006-12-05

7.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Authors:  Stephen Ross; Anthony Bossis; Jeffrey Guss; Gabrielle Agin-Liebes; Tara Malone; Barry Cohen; Sarah E Mennenga; Alexander Belser; Krystallia Kalliontzi; James Babb; Zhe Su; Patricia Corby; Brian L Schmidt
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

8.  Broadband cortical desynchronization underlies the human psychedelic state.

Authors:  Suresh D Muthukumaraswamy; Robin L Carhart-Harris; Rosalyn J Moran; Matthew J Brookes; Tim M Williams; David Errtizoe; Ben Sessa; Andreas Papadopoulos; Mark Bolstridge; Krish D Singh; Amanda Feilding; Karl J Friston; David J Nutt
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

9.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Authors:  Robin L Carhart-Harris; Mark Bolstridge; James Rucker; Camilla M J Day; David Erritzoe; Mendel Kaelen; Michael Bloomfield; James A Rickard; Ben Forbes; Amanda Feilding; David Taylor; Steve Pilling; Valerie H Curran; David J Nutt
Journal:  Lancet Psychiatry       Date:  2016-05-17       Impact factor: 27.083

10.  Neural correlates of the LSD experience revealed by multimodal neuroimaging.

Authors:  Robin L Carhart-Harris; Suresh Muthukumaraswamy; Leor Roseman; Mendel Kaelen; Wouter Droog; Kevin Murphy; Enzo Tagliazucchi; Eduardo E Schenberg; Timothy Nest; Csaba Orban; Robert Leech; Luke T Williams; Tim M Williams; Mark Bolstridge; Ben Sessa; John McGonigle; Martin I Sereno; David Nichols; Peter J Hellyer; Peter Hobden; John Evans; Krish D Singh; Richard G Wise; H Valerie Curran; Amanda Feilding; David J Nutt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-11       Impact factor: 12.779

View more
  84 in total

Review 1.  REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

2.  Psychedelics and connectedness.

Authors:  R L Carhart-Harris; D Erritzoe; E Haijen; M Kaelen; R Watts
Journal:  Psychopharmacology (Berl)       Date:  2017-08-10       Impact factor: 4.530

3.  Lucy in the sky with ketamine: Psychoactive drugs have potential for a major breakthrough in treating depression.

Authors:  Katrin Weigmann
Journal:  EMBO Rep       Date:  2018-10-15       Impact factor: 8.807

4.  Serotonin, psychedelics and psychiatry.

Authors:  Robin L Carhart-Harris
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

Review 5.  Translating Molecular and Neuroendocrine Findings in Posttraumatic Stress Disorder and Resilience to Novel Therapies.

Authors:  Jonathan DePierro; Lauren Lepow; Adriana Feder; Rachel Yehuda
Journal:  Biol Psychiatry       Date:  2019-07-24       Impact factor: 13.382

6.  Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice.

Authors:  Mario de la Fuente Revenga; Urjita H Shah; Nima Nassehi; Alaina M Jaster; Prithvi Hemanth; Salvador Sierra; Malgorzata Dukat; Javier González-Maeso
Journal:  ACS Chem Neurosci       Date:  2021-01-05       Impact factor: 4.418

Review 7.  Regulation of human research with LSD in the United States (1949-1987).

Authors:  Katherine R Bonson
Journal:  Psychopharmacology (Berl)       Date:  2017-11-17       Impact factor: 4.530

8.  Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse.

Authors:  Marcus W Meinhardt; Cansu Güngör; Ivan Skorodumov; Lea J Mertens; Rainer Spanagel
Journal:  Neuropsychopharmacology       Date:  2020-05-05       Impact factor: 7.853

9.  5-HT2A receptor activation normalizes stress-induced dysregulation of GABAergic signaling in the ventral tegmental area.

Authors:  Blake A Kimmey; Alexey Ostroumov; John A Dani
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-05       Impact factor: 11.205

10.  Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.

Authors:  Franz X Vollenweider; Alan Anticevic; Katrin H Preller; Joshua B Burt; Jie Lisa Ji; Charles H Schleifer; Brendan D Adkinson; Philipp Stämpfli; Erich Seifritz; Grega Repovs; John H Krystal; John D Murray
Journal:  Elife       Date:  2018-10-25       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.